Keyphrases
Acute Myeloid Leukemia
100%
Acute Myeloid Leukemia Cells
9%
Blast Cells
9%
Bone Marrow Cells
9%
Bone Marrow Samples
9%
Broad Response
9%
CD34+CD38-
9%
CD45+
18%
Chemotherapy Resistance
9%
Clinical Phases
9%
Clinical Usefulness
9%
Cytarabine
9%
Disease Model
9%
Doxorubicin
9%
Functional Precision Medicine
9%
Genetic Modification
9%
Genome Integrity
9%
Hematological Cancer
9%
Hematological Malignancies
9%
Highly Sensitive
9%
Improved Survival
9%
Intracellular Reactive Oxygen Species
9%
Leukemia Disease
9%
Leukemia Progression
9%
Leukemia Therapy
9%
Leukemic Stem Cells
18%
Leukemogenesis
9%
Mitotic Arrest
100%
MTH1
9%
MTH1 Inhibitors
100%
Normal Bone Marrow
9%
Novel Anticancer Agent
9%
Oxidative DNA Damage
100%
Oxidized nucleotides
9%
Phase I Trial
9%
Preclinical Data
9%
Reactive Oxygen Species
9%
Reactive Oxygen Species Level
18%
Response Profiles
18%
Targeted Treatment
9%
Therapeutic Window
9%
Treatment Standards
18%
Medicine and Dentistry
Acute Myeloid Leukemia
100%
Anticarcinogen
8%
Blast Cell
8%
Bone Marrow Cell
8%
Cytarabine
8%
Disease Model
8%
DNA Damage
8%
DNA Damage Checkpoint
100%
Doxorubicin
8%
Ex Vivo
8%
Hematologic Malignancy
8%
Leukemia Cell
8%
Leukemogenesis
8%
Malignant Neoplasm
16%
Mitosis Inhibition
100%
Personalized Medicine
8%
Phase I Trials
8%
Reactive Oxygen Species
25%
Stem Cell
16%
Therapeutic Window
8%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
100%
Anticarcinogen
8%
Chemotherapy
8%
Cytarabine
8%
Disease Model
8%
Doxorubicin
8%
Hematologic Malignancy
8%
Leukemogenesis
8%
Malignant Neoplasm
16%
Phase I Trials
8%
Reactive Oxygen Metabolite
25%
Therapeutic Window
8%